Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Regulus appoints Neil Gibson chief scientific officer

This article was originally published in Scrip

Executive Summary

Regulus Therapeutics, a La Jolla, California-based biopharmaceutical company focused on the discovery and development of new medicines targeting microRNAs, has named Dr Neil Gibson chief scientific officer. In this role, he will be responsible for leading all of the company's R&D efforts. Dr Gibson joins from the oncology research unit at Pfizer, where he was most recently chief scientific officer and oncology therapeutic area head. He also held leadership roles in Pfizer's oncology business unit leadership team and in the global leadership team of Pfizer’s pharmatherapeutics organisation.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts